{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:36:06Z","timestamp":1771590966124,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-018-1890-x","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T04:34:13Z","timestamp":1543898053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Giant prolactinoma, germline BRCA1 mutation, and depression: a case report"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7217-0509","authenticated-orcid":false,"given":"Rita","family":"Bettencourt-Silva","sequence":"first","affiliation":[]},{"given":"Joana","family":"Queir\u00f3s","sequence":"additional","affiliation":[]},{"given":"Josu\u00e9","family":"Pereira","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"key":"1890_CR1","doi-asserted-by":"publisher","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014;170:R213\u201327.","journal-title":"Eur J Endocrinol"},{"key":"1890_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.12242","volume":"79","author":"AB Moraes","year":"2013","unstructured":"Moraes AB, Silva CM, Vieira Neto L, Gadelha MR. Giant prolactinomas: the therapeutic approach. Clin Endocrinol. 2013;79:447\u201356.","journal-title":"Clin Endocrinol"},{"key":"1890_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2016.00025","volume":"7","author":"L Torner","year":"2016","unstructured":"Torner L. Actions of Prolactin in the Brain: From Physiological Adaptations to Stress and Neurogenesis to Psychopathology. Front Endocrinol (Lausanne). 2016;7:25.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1890_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.maturitas.2016.05.014","volume":"93","author":"KG Vargas","year":"2016","unstructured":"Vargas KG, Milic J, Zaciragic A, et al. The functions of estrogen receptor beta in the female brain: A systematic review. Maturitas. 2016;93:41\u201357.","journal-title":"Maturitas"},{"key":"1890_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1530\/eje.0.1510061","volume":"151","author":"N Sonino","year":"2004","unstructured":"Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava GA. Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol. 2004;151:61\u20135.","journal-title":"Eur J Endocrinol"},{"key":"1890_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrendo.2014.181","volume":"11","author":"AL Lecoq","year":"2015","unstructured":"Lecoq AL, Kamenicky P, Guiochon-Mantel A, Chanson P. Genetic mutations in sporadic pituitary adenomas--what to screen for? Nat Rev Endocrinol. 2015;11:43\u201354.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1890_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2001-0036","volume":"24","author":"CV Clevenger","year":"2003","unstructured":"Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev. 2003;24(1):1\u201327.","journal-title":"Endocr Rev"},{"issue":"3","key":"1890_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/00313029700169205","volume":"29","author":"I Strungs","year":"1997","unstructured":"Strungs I, Gray RA, Rigby HB, Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology. 1997;29(3):320\u20133.","journal-title":"Pathology"},{"issue":"6","key":"1890_CR9","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/BF03351047","volume":"24","author":"F Forloni","year":"2001","unstructured":"Forloni F, Giovilli M, Pecis C, et al. Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Investig. 2001;24(6):454\u20139.","journal-title":"J Endocrinol Investig"},{"issue":"3","key":"1890_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/15384047.2017.1294284","volume":"18","author":"Y Zheng","year":"2017","unstructured":"Zheng Y, Mo W, Yu Y, et al. Breast carcinoma associated with prolactinoma: A case report. Cancer Biol Ther. 2017;18(3):132\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"17","key":"1890_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13058-015-0563-6","volume":"31","author":"K Tikk","year":"2015","unstructured":"Tikk K, Sookthai D, Fortner RT, et al. Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study. Breast Cancer Res. 2015;31(17):49.","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1890_CR12","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/annonc\/mdu150","volume":"25","author":"K Tikk","year":"2014","unstructured":"Tikk K, Sookthai D, Johnson T, et al. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann Oncol. 2014;25(7):1422\u20138.","journal-title":"Ann Oncol"},{"key":"1890_CR13","doi-asserted-by":"publisher","first-page":"25998","DOI":"10.1038\/srep25998","volume":"6","author":"M Wang","year":"2016","unstructured":"Wang M, Wu X, Chai F, Zhang Y, Jiang J. Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep. 2016;6:25998.","journal-title":"Sci Rep"},{"key":"1890_CR14","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-05-3369","volume":"66","author":"SS Tworoger","year":"2006","unstructured":"Tworoger SS, Sluss P, Hankinson SE. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 2006;66:2476\u201382.","journal-title":"Cancer Res"},{"key":"1890_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s11102-009-0214-y","volume":"13","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Romijn JA, de Boer A, Vandenbroucke JP. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary. 2010;13:195\u20138.","journal-title":"Pituitary"},{"issue":"2","key":"1890_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1530\/EJE-11-0076","volume":"165","author":"K Berinder","year":"2011","unstructured":"Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol. 2011;165(2):209\u201315.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1890_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ijc.2910340307","volume":"34","author":"W Holtkamp","year":"1984","unstructured":"Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer. 1984;34(3):323\u20138.","journal-title":"Int J Cancer"},{"key":"1890_CR18","doi-asserted-by":"publisher","unstructured":"Bakhtou H, Olfatbakhsh A, Deezagi A, Ahangari G. The expression of dopamine receptors gene and their potential role in targeting breast cancer cells with selective agonist and antagonist drugs. Could it be the novel insight to therapy? Curr Drug Discov Technol. 2018. \n                    https:\/\/doi.org\/10.2174\/1570163815666180130101421\n                    \n                  . [Epub ahead of print]","DOI":"10.2174\/1570163815666180130101421"},{"issue":"3","key":"1890_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10549-017-4370-x","volume":"165","author":"R Costa","year":"2017","unstructured":"Costa R, Santa-Maria CA, Scholtens DM, et al. A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2017;165(3):585\u201392.","journal-title":"Breast Cancer Res Treat"},{"key":"1890_CR20","volume-title":"GeneReviews(R)","author":"N Petrucelli","year":"1993","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, et al., editors. GeneReviews(R). Seattle: University of Washington; 1993."},{"key":"1890_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10552-013-0156-6","volume":"24","author":"TV Clendenen","year":"2013","unstructured":"Clendenen TV, Arslan AA, Lokshin AE, Liu M, Lundin E, Koenig KL, et al. Circulating prolactin levels and risk of epithelial ovarian cancer. Cancer Causes Control. 2013;24:741\u20138.","journal-title":"Cancer Causes Control"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1890-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T19:09:29Z","timestamp":1575572969000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1890-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1890-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Our Institutional Review Board approved the search of electronic medical records for this paper. The patient involved gave consent for the use of her medical records.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"360"}}